KEDPLASMA

kedrion.com

KEDPLASMA specializes in the collection of high-quality plasma that is processed into plasma-based therapies to respond to patients’ needs the world over. KEDPLASMA is a subsidiary of Kedrion Biopharma, an international company that produces and distributes plasma-derived medicinal products for use in treating serious disorders such as hemophilia and immune system deficiencies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

news image

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More

Business Insights

VETSOURCE UNVEILS NEW BRAND REFLECTING COMPANY'S GROWTH

Vetsource | November 17, 2022

news image

Vetsource®, a pet health company designed to provide innovative pharmacy, technology and business services to those who care for pets, launched a new brand identity to signal the official start of three brands coming together as a single, unified portfolio of solutions for the veterinary industry. Already established as a leading provider of innovative prescription management and home delivery services for veterinary practices and pet owners since 2008, Vetsource announced the...

Read More

JUBILANT RADIOPHARMA AND SOFIE BIOSCIENCES INK STRATEGIC COLLABORATION AGREEMENT TO FURTHER ADVANCE THE FIELD OF MOLECULAR IMAGING & THERAPEUTICS

SOFIE Biosciences, Inc. | November 05, 2020

news image

SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to contin...

Read More

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

news image

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More
news image

Business Insights

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More
news image

Business Insights

VETSOURCE UNVEILS NEW BRAND REFLECTING COMPANY'S GROWTH

Vetsource | November 17, 2022

Vetsource®, a pet health company designed to provide innovative pharmacy, technology and business services to those who care for pets, launched a new brand identity to signal the official start of three brands coming together as a single, unified portfolio of solutions for the veterinary industry. Already established as a leading provider of innovative prescription management and home delivery services for veterinary practices and pet owners since 2008, Vetsource announced the...

Read More
news image

JUBILANT RADIOPHARMA AND SOFIE BIOSCIENCES INK STRATEGIC COLLABORATION AGREEMENT TO FURTHER ADVANCE THE FIELD OF MOLECULAR IMAGING & THERAPEUTICS

SOFIE Biosciences, Inc. | November 05, 2020

SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to contin...

Read More
news image

PREMIER INC. SUPPORTS FDA, DEA REFORMS AND REGULATORY WAIVERS TO COUNTER DRUG SHORTAGES

Premier Inc. | July 24, 2020

Premier Inc. today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company believes should be extended beyond the COVID-19 pandemic and made permanent thereafter in order to prevent drug shortages. “During the height of the COVID-19 pandemic, we saw demand for many common pharmaceuticals surge by an average of more than 150 percent,” said Blair Childs, Premier...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us